WE CAN HELP
Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Browse by Category

Treating Alopecia Universalis with Xeljanz May Have Serious Side Effects

Tofacitinib citrate, a potential ‘miracle cure’ for hair loss from Alopecia Universalis, has hit the headlines in recent days after the product regrew the hair of a man with this severe condition which causes total baldness.  What we have been surprised to see here at The Belgravia Centre is the fact that none of the tabloids have reported on the risk of serious side effects that come with the use of this medication. These side effects include serious infections, tuberculosis and cancer. We examine the condition, this latest treatment and the studies surrounding the controversial drug.

Alopecia Universalis

There are three main forms of Alopecia with Alopecia Universalis being the rarest and the most severe kind. Caused by a genetic mutation of the chromosomes, this type of Alopecia is believed to be an autoimmune disorder. The condition can occur at any age and causes a total loss of hair on the scalp and body – including eyelashes and eyebrows – and can also damage nails. Whilst the hair does spontaneously grow back for some sufferers, even years after the onset of the condition, it cannot be predicted if or when this regrowth will occur.

There is currently no cure for Alopecia Universalis although a range of treatments have been explored, the most recent being the rheumatoid arthritis drug, Tofacitinib Citrate.

Tofacitinib Citrate (brand name, Xeljanz)

Arthritis Drug Used to Treat Hair Loss from Alopecia Universalis in Yale University Study

Made by Pfizer using the brand name Xeljanz, tofacitinib citrate is a Janus-associated kinase (JAK) inhibitor which works inside cells to disrupt intracellular activities inside the JAK pathways. These are paths within our cells that are used by some signalling proteins (cytokines) to help control immune and inflammatory responses. It is a small, film-coated pill which is taken orally.

Tofacitinib citrate was approved by the FDA for the treatment of moderate to severe cases of the autoimmune disease, rheumatoid arthritis, in adults in November 2012 but was dogged by complaints – firstly about the cost, then about the side effects.

Xeljanz is currently FDA-approved for the treatment of rheumatoid arthritis in the USA and has also received similar approvals for use in Argentina, Columbia, Kuwait, the United Arab Emirates, Russia and Switzerland. Japan have also approved tofacitinib citrate for this type of treatment in adults, however, there it goes by the brand name Jaquinus.

The drug – which is unavailable in the UK as it has not been granted a license by the Medicines and Healthcare products Regulatory Agency (MHRA) – had previously been used to successfully treat psoriasis in humans and to reverse lesser forms of alopecia in mice.

Results of the Yale University of Medicine Study Using Tofacitinib Citrate to Treat Alopecia Universalis

Scientists at America’s elite Yale University School of Medicine used the drug to treat a 25 year old patient who was referred to them for treatment of plaque psoriasis, a chronic immune-mediated skin disease, and the most common strain of psoriasis, which displays as inflamed, scaly skin.

However, his diagnosis of Alopecia Universalis – which had never been treated – was also noted by the medical team and they decided upon the tofacitinib citrate treatment in order to try to cure both conditions.

The unnamed patient was almost completely hairless when he started the treatment, with the only hair being within the psoriasis plaques on his scalp.

After taking an 8 month course of tofacitinib citrate which involved 10mg per day for two months, followed by 15mg of the drug per day for another three months, the treatment was deemed to be ‘mildly effective’ in treating the patient’s psoriasis, however, he saw amazing results in terms of hair regrowth.

The subject had completely regrown scalp hair, developed eyebrows, eyelashes and facial hair, armpit hair and other hair – the first hair the man had grown in seven years.

This Yale study is the first reported case of a successful, targeted treatment for the rare Alopecia Universalis condition.

The paper detailing the Yale study, “Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis” was written by Brett A. King, M.D., assistant professor of dermatology at Yale University School of Medicine and his dermatologist colleague, Brittany G. Craiglow, M.D.

Dr. King explained, “The results are exactly what we hoped for. This is a huge step forward in the treatment of patients with this condition. While it’s one case, we anticipated the successful treatment of this man based on our current understanding of the disease and the drug. We believe the same results will be duplicated in other patients, and we plan to try.”

He concluded, “There are no good options for long-term treatment of alopecia universalis. The best available science suggested this might work, and it has.”

Clinical Trials & the Reported Side Effects of Xeljanz

The study’s co-author, Dr. Craiglow, said, “By eight months there was full regrowth of hair. The patient has reported feeling no side effects, and we’ve seen no lab test abnormalities, either.”

The results from this study are extremely encouraging, however, further, wider-scale clinical trials are required in order to establish whether the use of tofacitinib citrate in combating Alopecia Universalis, as well as potentially other forms of hair loss, is safe. Particularly given the alarming side effects associated with the drug in connection with its treatment of rheumatoid arthritis in adults and various other conditions it has been tested for as a potential remedy, including Crohn’s disease, dry eyes, plaque psoriasis, renal transplant rejection,ulcerative colitis, and ankylosing spondylitis.

Many clinical trials of Xeljanz have been, and continue to be carried out in relation to the drug’s suitability and safety as a treatment for rheumatoid arthritis and psoriasis. Yale’s Dr. King has already submitted a proposal for a clinical trial involving a cream form of tofacitinib as a treatment for alopecia areata.

Phase III clinical trials for the study into the Long-Term Effectiveness And Safety Of Tofacitinib For The Treatment Of Rheumatoid Arthritis are still under way, with results expected in 2019. However, the Phase II trials tested Xeljanz in Rheumatoid Arthritis patients that had not responded to other therapy and found the most important side effects to be increased blood cholesterol levels  (12 to 25 mg/dl LDL and 8 to 10 mg/dl HDL at medium dosage levels) and neutropenia, a granulocyte disorder whose key symptom is a deficit of white blood cells which can then lead to an increased risk of infection.

Currently scheduled until November 2019, on-going clinical trials for the drug started in February 2007. In April 2011, four patients died after beginning clinical trials with tofacitinib citrate; Pfizer said that only one of the four deaths was related to tofacitinib.

In April 2013, Arthritis Research UK reported that the European Medicines Agency (the regulatory body in charge of drug approvals in the EU) had been advised not to approve tofacitinib for treatment of rheumatoid arthritis, saying ‘The European Medicines Agency (EMA) is unlikely to approve a new medication called tofacitinib citrate (brand name Xeljanz) for the treatment of adults with rheumatoid arthritis, after its Committee for Medicinal Products for Human Use (CHMP) failed to produce a positive recommendation… The committee also had “major concerns” about the medication’s safety with regard to serious infections, certain cancers, gastrointestinal perforations, liver damage and blood fat levels… Therefore, at that point in time, the CHMP was of the opinion that the benefits of Xeljanz did not outweigh its risks and recommended that it be refused marketing authorisation’.

Funmi Lampejo, Pharmacy Manager at The Belgravia Centre’s City of London clinic, explains, “Tofacitinib is an immunosuppresant. It works by damping down the immune system so that the progress and symptoms of diseases caused by the body’s own immune system attacking it can be slowed and relieved. The problem with that is that the body is not protected from opportunistic infections, and cancers are more likely to develop in the long term.”

“Essentially, they decided that the drug tofacitinib did not offer any added advantage over existing immunosuppressants, and had a worse adverse effect profile compared to drugs already on the market, particularly in patients with resistant rheumatoid arthritis. In addition, they were concerned about the incidences of serious side-effects such as cancers, infections and digestive tract problems. As the dose which may be effective for alopecia totalis and universalis has not yet been fully established, it may turn out that the adverse effect profile may improve. It is too early to speculate either way.”

The EMA’s Assessment report on Xeljanz from July 2013 highlighted a number of the European regulatory body’s ‘major concerns’ about the drug’s serious side effects and the Benefit-Risk balance.

Although the most common side effects of  Xeljanz in its usual role as rheumatoid arthritis medication, were found to be  upper respiratory tract infections, headaches, hypertension, diarrhoea and inflammation of the nasal passage (nasopharyngitis), the current Safety & Side Effects warnings on the product’s website and packaging clearly state that ‘Xeljanz may cause serious side effects’. These include:

  • Serious infections: ‘Some people have serious infections while taking Xeljanz , including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.’
  • Cancer and Immune System Problems: ‘Xeljanz may increase your risk of certain cancers by changing the way your immune system works.’
  • Tears (perforation) in the Stomach or Intestines: ‘Some people taking Xeljanz get tears in their stomach or intestine. This happens most often in people who also take non-steroidal, anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.’

The manufacturers also state that Xeljanz is not suitable for those with infections, liver, kidney or stomach problems including ulcers, and it should not by used by women who are, or are planning to become, pregnant. There are various other conditions where the drug is deemed unsuitable, such as if the patient has recently been vaccinated.

Alternative Treatments for Alopecia Universalis

Until the Tofacitinib Citrate study outlined above, the most effective treatment for Alopecia Universalis was thought to be topical Immunotherapy. This shocks the hair follicles into production by creating an allergic reaction on the affected areas of the skin. The treatment has a success rate of around 40% and needs to be ongoing for hair growth to continue, but reported side effects – most commonly including persistent dermatitis, generalized eczema and blistering – can be unpleasant.

Share this article

82 Comments

13th August, 2016 at 4:00 pm

shiny head

Hi. I stumbled across this site while researching alopecia universalis. I started losing my hair around 2008, andI lost the last of my hair around 2012. I did go through some treatments with my dermatologist with the tar shampoos, psoriasis (I don't have this) light treatment, Propecia, injections. but nothing worked. The only thing we didn't try was the allergic reaction. My nails are affected by this as well, as they are brittle I stopped treatment in 2013 Recently I went to a rheumatologist, due to my knuckles getting somewhat stiff, as another GP at my clinic thought that could be a cause of the AU, but was given a healthy green light. I suggested to my normal GP that the AU is stress related and he pretty much laughed. Blood work comes back with no abnormalities, though I feel t-levels could be a bit higher. Outside of some mild fatigue I generally feel ok and don't have much issue with energy. That said, this whole thing is wrecked me and tends to keep me down. Any suggestions as to someone I can see in the Chicagoland area that can help deal with this AU? Thanks for taking the time to read this.

15th August, 2016 at 9:42 am

Sarah Belgravia

Hi there, I'm afraid we can't recommend anyone to you but if you contact the NAAF (National Alopecia Areata Foundation) they should be able to help you. Very best of luck.

26th September, 2016 at 8:41 am

Anonymouse

I have a mild form of alopecia areata with a couple bald spots at the lower back of my head near my neck. They're easy to hide and aren't that much of a nuisance but I would still like to get it treated. I want to try out the topical cream form of tofacitnib but when reading the side effects, I notice the section which states that people that have taken corticosteroids are at a higher risk of stomach and intestinal tears. I've taken corticosteroids in the form of injections in my AA bald spots. Does that mean that I'm at a higher risk for the side effects of tofacitnib? How long should I, and everyone else with AA, wait for the tofacitnib clinical trial results?

28th September, 2016 at 12:29 pm

Daphne Janes

I also have AU and have had this for 15 years.. otherwise very healthy. Would love to know more about trials in the eastern side of the state.. if I can help, I would love to.. even though it may not help me. I have dealt with it this long and am okay with it. Thanks.. Daphne zjanes

5th October, 2016 at 1:45 pm

Sarah Belgravia

Hi Daphne, the only trials we are aware of are taking place in New York and are not currently recruiting but if you contact the university directly they may be able to help you further.

5th October, 2016 at 1:47 pm

Sarah Belgravia

Hi Anonymouse, we cannot provide or speculate about medical advice in relation to this as tofacitinib is still in the very early stages of testing in both oral and topical forms. It is likely to be 2020 at the earliest that we see significant progress with this drug but we will post updates as to its progress here on the Belgravia hair loss blog.

18th October, 2016 at 4:18 am

Rudy Saenz

Good evening. My son developed alopecia areata. He is 14 years old. It has turned his life upside down now being a freshman in high school. I want to help my son. I would like to see if they would allow him to be in the clinical trials for the Xeljanz. Please consider him. He is healthy except for the Alopecia Areat and some mild psoriasis. Thank you for your help.

18th October, 2016 at 9:16 am

Sarah Belgravia

Hi Rudy, Unfortunately we are not involved in these trials so cannot help your son. The best thing to do if you are interested is to contact the University who is running the trials directly. However, we believe they are not accepting new volunteers at present. If your son has alopecia areata - patchy hair loss on his scalp rather than baldness from alopecia totalis or alopecia universalis - then treatment is available from 16 years of age.

23rd October, 2016 at 6:03 am

Abhi

I m suffering from AU since my birth. My nails of hands n legs r also wrinkled or dekay. Plz suggest me d best result oriented treatment. M 19yr young.

24th October, 2016 at 4:27 pm

Sarah Belgravia

Hi Abhi, there is currently no truly effective treatment for alopecia universalis. There are some promising drugs being trialled at the moment so there is hope that a treatment will be discovered in the next few years. You can read more about these on the Alopecia section of the Belgravia blog. However, at present there are no treatments for the hair loss or dermatological effects of this condition. Sorry we do not have better news for you.

12th December, 2016 at 9:58 pm

Susan Giovanniello

My 16 year old son has AU and is currently being treated with xeljanz. His hair is growing back. He was treated with plaquinol prior for 6 months. He is seeing the doctor from Yale who has been using xeljanz to treat alopecia in experimental trials and made the discovery that it was effective

13th December, 2016 at 11:03 am

Sarah Belgravia

That's great to hear, Susan! We're looking forward to hearing the results of the trials on a long term basis. Please do keep us updated, it sounds like xeljanz could be a fantastic treatment if it meets relevant safety criteria.

27th December, 2016 at 4:04 pm

Jeff

Hello. I would like to have details on where to access this treatment. How can I get in contact with the doctors?

11th January, 2017 at 2:08 pm

Sarah Belgravia

Hi Jeff, You would need to contact Yale University directly - they should be able to help you.

18th January, 2017 at 5:31 pm

DM

When you google alopecia areata xeljanz the first hit is your site. Which has title of side effects of xeljanz. I dont think it is fair that you are belittling the effort of scientists who are trying to help people. Every medicine has side effects..clinical trials have not shown serious side effects yet. Maybe if they did find a treatment your business woll be jeopardized.

18th January, 2017 at 5:51 pm

Sarah Belgravia

Hi DM, we do not treat Alopecia Universalis and Alopecia Totalis so this has no impact on our business - if anything, we may consider treating these conditions if a safe and effective treatment is discovered! The possible side effects of these drugs are well known due to their particular seriousness, which is why the researchers are currently investigating ways in which to minimise these risks, such as by applying the drug topically rather than taking it in its usual oral form for example. We are in no way belittling the work of these outstanding researchers and are hopeful that their work will develop - as it has been doing since this initial article was first published over two years ago - to the point where a clinically-proven treatment for these severe forms of hair loss becomes available. We hope this puts your mind at rest.

23rd January, 2017 at 5:09 pm

Rick Albert

Hi my son was recently at Yale and has been approved to begin Xeljanz this week....however I'm obviously very concerned that taking this drug will dampen his immune system....he's 15 very athletic and fit....can u tell us more or lead us to the details around the death or deaths reported from the use of this drug ??

23rd January, 2017 at 6:01 pm

Sarah Belgravia

Hi Rick, your son should speak to the doctors who are treating him at Yale. They will be able to provide him - and you - with the relevant information and can also explain how it pertains to the doses being given to your son. You can also read the list of potential side effects on the Xeljanz patient information leaflet which is available online beforehand if you wish to learn about these so you can discuss them with your son's treatment team. We wish him the very best of luck and hope his treatment is going well.

31st January, 2017 at 7:01 pm

Jillian

Hello. I have AU, for past 2 years. I had AA about 7 years ago but full regrowth. Also gave Crohns and Psoriatic Arthritis - take Humira and Methotrexate. Derm feels I qualify for xeljanz, said to go off Metho, but upon remembering my taking Humira for Crohns for last 10 years said I don't qualify for the trial. My question is, will I see a day in the near future where my gastroenterologist would prescribe xeljanz for IBD - hopefully do some double duty for me???

1st February, 2017 at 5:12 am

Mel

Hi, I've had AA then Totalis since I was about 13 years of age. And they grew back completely a few years later. But then, I started feeling patches again and in a matter of one year, it turned into AU. Do you know anything about whether or not this new drug will permanently prevent hair loss again if my hair were to grow back? And also, after the hair grows back, do we have to keep taking the drug in order to keep the hair or is there a time where we can stop taking the drug all together? Thank you.

1st February, 2017 at 1:04 pm

Sarah Belgravia

Hi Jillian, we cannot give you this type of medical advice - you would need to speak with your treatment team for this.

1st February, 2017 at 1:07 pm

Sarah Belgravia

Hi Mel, these are all scenarios being explored during the trials. None of this is known yet but we hope for announcements on this type of information as the trials proceed. When this information does become available we will publish updates on our hair loss blog.

2nd March, 2017 at 7:30 pm

Frank W Nash

Thank god it is safe for RA victims. I am sure it is totally unsafe for AA.

10th March, 2017 at 6:47 pm

Phil

Hi. I had patches come and go since age 13. I'm 42 now and lost every hair on my body in 3 months. Super depressed now. Don't like drugs. But I don't like depression either. Fake brows and lashes and wigs or drugs? I am full of questions. And doesn't look like any answers can be given to me. My nails look like they want to fall off.

13th March, 2017 at 11:26 am

Sarah Belgravia

Hi Phil, sorry to hear this. Unfortunately we cannot treat Alopecia Universalis at the current time but you may find this update on JAK inhibitor drugs of interest.

13th March, 2017 at 2:24 pm

Sarah Belgravia

Hi Frank. So far the clinical trials have found that the drug is well tolerated with minimal side effects for Alopecia Areata patients. However, the researchers concede that larger scale trials are needed and hope to move on to these soon. You can find out more in this latest update.

7th April, 2017 at 2:54 am

Natalie

I started losing my hair at the age of 22 and became alopecia Areata by the age of 23. All my blood work come back normal and I'm a fairly healthy Asian 42 year old female with no major health conditions. I live in Dallas, Texas and would like to explore the options of clinical trials with this diagnosis. More importantly, when will the topical treatments be available?

7th April, 2017 at 1:57 pm

Sarah Belgravia

Hi Natalie, we are not involved in these trials - you would need to contact the universities carrying them out directly - however you can find information on expected release dates for JAK inhibitor hair loss treatments on our blog. Please bear in mind that as these are still in trials, these estimated dates are based on no hiccups occurring and the drugs passing all necessary safety, tolerability and efficacy tests required before being made available for prescription. There are already effective alopecia areata treatment options available so do get in touch or browse our success stories if you would like to know more about these.

25th April, 2017 at 3:49 pm

Jessica

hello, my 4 year old daughter hAA and is being evaluated by her dermatologist to begin taking Xeljanz. Is there any danger or side effects for children with this drug?

26th April, 2017 at 9:53 am

Sarah Belgravia

Hi Jessica, you will need to speak with your dermatologist or whoever intends to prescribe her the Xeljanz about medical advice. We cannot provide you with this as we do not offer Xeljanz given it has not yet been MHRA approved as a treatment for alopecia areata or any other form of hair loss. They should talk you through all the potential side effects before you make the decision about your daughter starting any treatment. Best of luck.

28th April, 2017 at 8:23 am

Parth

hi i am from india and im suffering from alopecia universalis from last 12 years many type of medicine ill try but no one can effect in alopecia now iam hearing about tofacitinb citrate and i am starting treatment if any kind of upgrade ill write here

28th April, 2017 at 11:07 am

Sarah Belgravia

That's good to hear, Parth. Best of luck and we look forward to hearing from you as to how you're getting on with this treatment.

Comment on this article

* required field

Will not be published

Online Consultation

Submit an instant online consultation so that one of Belgravia’s hair loss specialists can diagnose your condition and recommend an effective course of treatment, wherever you live.